Pablo Legorreta

Pablu Legorreta is the Co-Founder and serves as Chief Executive Officer at Royalty Pharma. He serves as investment Manager at BioPharma Credit PLC. He is the Founder of Pharmakon Pharmaceuticals. He was a Board Member at Atentiv. Legorreta founded Royalty Pharma in 1996. Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property, with over $15 billion in royalty assets. Royalty Pharma funds innovation in life sciences, indirectly, when it acquires existing royalty interests from the original innovators (academic institutions, research hospitals, foundations, and inventors) or, directly, when it partners with life sciences companies to co-develop and co-fund products in late-stage human clinical trials. Prior to founding Royalty Pharma, Legorreta spent a decade at Lazard Frres in Paris and New York where he provided cross-border merger and acquisition and corporate finance advisory services to European and U.S. corporations. Legorreta serves on the Board of Governors of the New York Academy of Sciences, and the Boards of Trustees of the Hospital for Special Surgery, the Pasteur Foundation (U.S. affiliate of the French Institut Pasteur), The Open Medical Institute, The Park Avenue Armory, and Grace Church School. Legorreta founded and is currently Chairman of Alianza Medica para la Salud (AMSA), a privately-funded, not-for-profit foundation whose goal is to educate Latin American doctors and healthcare providers to improve the quality of healthcare in Latin America. Legorreta received a degree in industrial engineering from Universidad Iberoamericana (Mexico City). He also served as Senior Advisor at Marker.